NCT06547242View on ClinicalTrials.gov

Levothyroxine-sodium Bioequivalence Trial With Oral Single Dose Administration

PHASE1CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

October 22, 2021

Primary Completion Date

March 22, 2022

Study Completion Date

May 22, 2022

Conditions
Healthy
Interventions
DRUG

Levothyroxin

Single-dose administration of 600 mcg of Levothyroxin for the assessment of bioequivalence

DRUG

Levothyroxin

Single-dose administration of 600 mcg of Levothyroxin for the assessment of bioequivalence

Trial Locations (1)

99084

Phase I Unit, Erfurt

All Listed Sponsors
lead

Berlin-Chemie AG Menarini Group

INDUSTRY

NCT06547242 - Levothyroxine-sodium Bioequivalence Trial With Oral Single Dose Administration | Biotech Hunter | Biotech Hunter